Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.

Vinay Gupta, Yuzhuang S. Su, Weijun Wang, Adel Kardosh, Leonard F. Liebes, Florence M. Hofman, Axel H. Schönthal, Thomas C. Chen

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

OBJECT: The chemotherapeutic agent temozolomide has demonstrated antitumor activity in patients with recurrent malignant glioma. Because responses are not enduring and recurrence is nearly universal, further improvements are urgently needed. METHODS: In an effort to increase the clinical activity of temozolomide, the authors investigated whether its antitumor activity could be enhanced by adding tamoxifen or hypericin, two drugs that are known to inhibit the activity of protein kinase C. Human glioblastoma multiforme cell lines A172 and LA567 were treated with combinations of temozolomide and tamoxifen or hypericin in vitro, and cell survival was analyzed using various methods. Tamoxifen and hypericin were able to greatly increase the growth-inhibitory and apoptosis-stimulatory potency of temozolomide via the downregulation of critical cell cycle-regulatory and prosurvival components. Furthermore, with the use of an in vivo xenograft mouse model, the authors demonstrated that hypericin was able to enhance the antiglioma effects of temozolomide in the in vivo setting as well. CONCLUSIONS: Taken together, analysis of the results indicated that combination therapy involving temozolomide and tamoxifen or hypericin potently inhibited tumor growth by inducing apoptosis and provided an effective means of treating malignant glioma.

Original languageEnglish (US)
Pages (from-to)E20
JournalNeurosurgical focus
Volume20
Issue number4
DOIs
StatePublished - 2006

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.'. Together they form a unique fingerprint.

  • Cite this